@alkpositiveuk.bsky.socialIt’s #WorldRadiotherapyAwarenessDay.
Radiotherapy can also play an important role in ALK+ #lungcancer. It may be used to treat cancer in the brain or other parts of the body, control one or a small number of areas that have started growing, or relieve symptoms.
@respirology.bsky.socialRespirology September issue now online:
onlinelibrary.wiley.com/toc/14401843...
@wiley.com
#Asthma #Interventionalpulmonology #lungcancer
@lungcancereurope.bsky.socialNew microplastics research presented at #ERSCongress today studied 100 people undergoing tests for lung symptoms.
Microplastics were found in lung-wash samples from 66% of those diagnosed with #LungCancer, compared with 46% of those without it.
@btog.bsky.socialInnovate UK invests £25.4M to advance early cancer diagnosis. Apply by 28 Oct 2026! Details: https://ow.ly/8rYh50ZCn28 #CancerHealthcareGoals #LCSM #LungCancer
@tarespirdis.bsky.socialFascinating research presented by one of our Editorial Review Board members, Ilias Dimeas, at #ERSCongress2026 examining respiratory microplastic burden in patients with lung malignancy. #RespiratoryResearch #LungCancer #ERS2026
@lungcancereurope.bsky.socialAt #ERSCongress2026 today?
Come and meet us from 12:00–13:00 at the @europeanlung.bsky.social stand in the World Village and talk to us about #LungCancer in Europe. #LCSM
@genesndiseases.bsky.socialWhy do #EGFR inhibitors stop working?
This single-cell study identifies an HSPA6–FOLR2 macrophage axis that drives osimertinib resistance in #LungCancer, highlighting CCL2 blockade as a promising combination strategy.
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...
@lcrf.orgThank you to Parkway Real Estate for your support of the Free to Breathe Kansas City Walk! #FreeToBreathe #LungCancer #ThankYou
@lcrf.orgThe Free to Breathe Kansas City Walk to support #LungCancer research is just 3 weeks away! Join us Saturday, Sept 26 at Longview Lake Shelter #13. Sign up at lcrf.org/kc!
@dustcircle.bsky.social#Scientists Discover Hidden #Cells That Help #LungCancer Evade the #ImmuneSystem
@lungcancereurope.bsky.socialPeople affected by #lungcancer do not share their experiences with us so they can sit in a report.
At #ERSCongress, we’re taking what they told us into wider discussions and presenting two abstracts on Tuesday: one on SCLC and one on storytelling in lung cancer awareness. #LCSM
@estroradiotherapy.bsky.social🎯 How do you treat a moving target with precision? Breathing makes lung tumours hard to hit.
🎥 Dr Valeria Dionisi (Verona, IT) on MRI-guided lung #SBRT — seeing the tumour in real time, high safe doses in fewer sessions.
#RadOnc #lungcancer #WRAD
@markfortner.bsky.socialNewly approved pancreatic cancer drug shows promise in lung cancer | #cancer #PancreaticCancer #LungCancer #biotech
@vcclibrary.bsky.socialDaraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell #LungCancer. www.nejm.org/doi/10.1056/...
@vcclibrary.bsky.socialPerioperative Durvalumab for Resectable Non–Small Cell #LungCancer: Updated Outcomes From the Phase III AEGEAN Trial. ascopubs.org/doi/10.1200/...
@lungcancereurope.bsky.social200+ people have registered for today’s #SCLC webinar. There’s still time to join us.
We’ll hear from people living with SCLC and others affected by it, alongside clinicians, about diagnosis, treatment and support.
15:00 CEST / 14:00 BST
@alkpositiveuk.bsky.socialNew research is helping us understand why ALK targeted treatments can stop working.
In 148 people with ALK+ #lungcancer, researchers identified changes in the RAS pathway as one possible route of resistance.
An important clue for future research.
@thecancersurvivorsclub.comEncouraging development for daraxonrasib. New trial results suggest the approved pancreatic cancer drug may also have potential against RAS-mutated non-small-cell lung cancer, with tumours shrinking in more than 30% of participants.